Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medaxes Sets Out Hopes For Belgian Biosimilars Taskforce

INAMI Taskforce Met For The First Time In Late January

Executive Summary

Belgian off-patent industry association Medaxes has set out its aspirations for a new biosimilars taskforce that has been set up by local health insurance body INAMI. Data cited by the industry body shows that biosimilar penetration in Belgium is still lagging behind that of its European neighbors.

You may also be interested in...



Belgian Legislation Offers Potential Biosimilar Boost

Draft legislation published this month in Belgium offers the country greater guidance that could help boost the uptake of “under-utilized” medicines in hospitals, including biosimilars.

Belgium Hails Biosimilars Breakthrough In Insurers’ Deal

Biosimilars have been given a potential boost in Belgium after the latest agreement between health insurers and prescribing doctors included a commitment to contribute to a biosimilars taskforce aimed at driving uptake. Initially introduced in early 2020, the taskforce is due to be relaunched in 2022.

European Biosimilars Can Benefit From Sharing Experiences

Attendees to Medicines for Europe’s virtual summit on biosimilars heard how learning from experiences across Europe can allow individual countries to build a toolbox of policies to help create a sustainable biosimilars market.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB149635

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel